Wednesday, 10 August, 2022
TopicCovid vaccine

Topic: Covid vaccine

Chances of Covid vaccine by this year is ‘very low’, says Boris Johnson’s medical adviser

The assessment came despite the Oxford vaccine effort showing promising results in early human testing and is a sign of ongoing uncertainty over the likelihood of quick success.

Immunotherapy could be safe for cancer patients with Covid, early data indicates

From nanoparticle vaccine to antibody cocktail for treatment, ThePrint brings you the latest research on the novel coronavirus.

Two shots of Covid vaccine may be better than one, but that makes it all very complicated

Early study of more than 1,000 participants receiving the Oxford vaccine achieved the strongest immune response in 10 who received two doses, says research published in The Lancet.

Why we should not hype the hope for the Oxford-AstraZeneca Covid vaccine

It's important to remember that at this early stage in the process, every piece of vaccine data is still just part of a thesis that needs confirmation.

T cells produced, mild side effects — decoding why Oxford’s vaccine offers new Covid hope

The results of the phase 1 trials for the Oxford vaccine are preliminary, but indicate a likely chance of expedited vaccine delivery.

Great news on Covid vaccine as Oxford trial shows dual immune action against coronavirus

Oxford vaccine is at the front of 160 coronavirus vaccines in various stages of development. AstraZeneca may begin delivering doses to UK as early as September.

Covaxin trial process has begun, can get results in 2-3 months if all goes well, says AIIMS

AIIMS director Randeep Guleria says recruitment for the trial phases had begun and the process would be concluded as quickly as possible.

Scores of Russian elite have been given experimental Covid vaccine since April

Russian vaccine is a viral vector vaccine based on a common cold virus fused with spike protein of SARS CoV-2 to stimulate an immune response.

Made-in-India Covid vaccine likely by early 2021, Zydus Cadila chairman Pankaj Patel says

In an interview to ThePrint, Panjak R. Patel, chairman of Zydus Cadila, says company has already manufactured clinical batches of the vaccine candidate for phase 1 and 2 trials.

What are human challenge trials — the experiment Oxford is considering for its Covid vaccine

Oxford vaccine is under Phase II/III trials in multiple countries, where many have been given the vaccine & are being followed up with — a process that consumes time, but is standard. 

On Camera


Representational image | Indian Navy/Facebook

Tale of two ships – How Delhi is asserting Indianness of the Indian Ocean to China

A US Navy ship docked in an Indian port for the first time. And a Chinese ship couldn’t in Sri Lanka. New Delhi is finally pulling strings.
Representational image | Rupixen/Unsplash

‘We are cracking down’— how Modi govt plans to make it tougher for states to fund freebies

The Narendra Modi government is looking at ways to check states’ spending on handouts like free electricity and rations. The first step is to tighten the noose on state borrowings.


Representational image | Indian Army soldiers during the Army Day Parade at Cariappa Parade Ground in New Delhi | ANI Photo

Army looks to reduce troops by 2 lakh, deployment in Kashmir could be rejigged

The Army, which faces a shortage of about 1.35 lakh personnel, is aiming to reduce its strength from 12.8 lakh to around 10.8 lakh.

In Kashmir 3 years on, 3 positive changes, 3 things that should’ve happened & 3 that got worse

Kashmir as a crisis has fallen off our headlines and from the top of our collective minds. Which is precisely the most important change for the better.